HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Ciprofloxacin (Cipro)

Subscribe to New Research on Ciprofloxacin

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Also Known As:

Cipro; Bay-09867; Ciprinol; Ciprofloxacin Hydrochloride; Bay 09867; Bay09867; Hydrochloride, Ciprofloxacin; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-

Networked: 4530 relevant articles (787 outcomes, 709 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Quinolines: 92
    - Quinolones: 1190
      - Fluoroquinolones: 2005
        Ciprofloxacin: 4530
        Fleroxacin: 151
        Technetium Tc 99m ciprofloxacin: 42
        difloxacin: 34
        sarafloxacin: 14
        orbifloxacin: 12
        amifloxacin: 11
        ciprofloxacin dithiocarbamate: 3
        hydrocortisone drug combination ciprofloxacin: 3
        8-fluorociprofloxacin: 1
        Ro 24-4383: 1
        (ciprofloxacin)2(Bi2Cl10)
        1-cyclopropyl-6-fluoro-3-formyl-1,4-dihydro-4-oxo-7-piperazinylquinoline
        3Mix ointment
        6-fluoro-7-(1-piperazinyl)-1-(2'-phenyl-1'-cyclopropyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
        7-(2-aminoethoxy)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
        7-(2-aminoethylthio)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
        7-(2-aminomethylmorpholino)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
        99mTc-CPFXDTC
        amifloxacin N-oxide
        bismuth(III)-ciprofloxacin 1
        ciprofloxacin drug combination betacyclodextrin
        ciprofloxacin-7-ethylenediamine
        CNV9710
        FD 501
        N-(2-(4-fluorophenyl)-2-oxoethyl)ciprofloxacin
        N-(2-phenyl-2-oxoethyl)ciprofloxacin
        N-desmethylamifloxacin
        oxociprofloxacin
        PD 135042
        PD 160793
        PD 161148
        piperazinyl-cross-linked ciprofloxacin dimer
        pirfloxacin
        poly(1,6-hexanediisocyanate-co-polycaprolactonediol-co-ciprofloxacin)
        Ro 24-6392
        Ro 24-6778
        Ro 25-0534
        sulfociprofloxacin
        SYN 987
        SYN-1193
        SYN-1253
        WM5 compound

Experts

1.	Wall, G Michael: 12 articles (08/2011 - 12/2003)
2.	Roland, Peter S: 11 articles (12/2013 - 12/2003)
3.	Cho, Yong-Hyun: 10 articles (01/2014 - 04/2005)
4.	Kohno, Shigeru: 8 articles (07/2013 - 03/2003)
5.	Ko, Wen-Chien: 7 articles (07/2014 - 07/2003)
6.	Han, Chang Hee: 7 articles (01/2014 - 04/2005)
7.	Yanagihara, Katsunori: 7 articles (07/2013 - 12/2003)
8.	Hsueh, Po-Ren: 7 articles (06/2011 - 01/2005)
9.	Stahlmann, Ralf: 7 articles (03/2010 - 02/2002)
10.	Hirakata, Yoichi: 7 articles (08/2008 - 03/2003)

Related Diseases

1.	Infection 12/16/2004 - "Our patient was successfully treated with ciprofloxacin, which is effective against Francisella tularensis and most pathogens associated with feline infections. " 02/01/1994 - "Ciprofloxacin is an effective treatment for those infections most common in elderly patients, including infections of the urinary tract, lower respiratory tract, skin and soft-tissues, and bone and joints, and is an effective agent for prophylaxis in transurethral surgery. " 11/01/1992 - "Overall, the results show that ciprofloxacin is effective in killing methicillin-resistant staphylococcus aureus, and is most effective when applied during the very early stages of infection." 12/01/1989 - "It is concluded that a single 250 mg dose of ciprofloxacin is effective for treatment in most women with acute UTI, but in women with recurrent infection a 750 mg dose is preferable." 01/01/1987 - "Ciprofloxacin was well tolerated and effective in most of the ambulatory patients with refractory Gram-negative bacillary infection. "
2.	Urinary Tract Infections (Urinary Tract Infection) 05/01/1987 - "As the concentration of ciprofloxacin in urine after 24 h remained above the MIC for most urinary pathogens, this drug appears to be of potential benefit for the treatment of urinary tract infections in patients with impaired renal function." 03/01/2015 - "We conclude that ciprofloxacin is a safe and effective therapeutic alternative for the treatment of acute or complicated urinary tract infections in adults." 03/01/1996 - "The therapeutic efficacy of intravenous ciprofloxacin against experimentally induced urinary tract infections in mice was compared to that after oral dosing by determining viable bacteria count in kidney 24h after inoculation. " 03/01/1996 - "The therapeutic efficacy of intravenous ciprofloxacin against experimentally induced systemic, respiratory tract and urinary tract infections was investigated in mice. " 11/01/1986 - "Ciprofloxacin appears to be an effective and safe orally-administrable treatment even for complicated urinary tract infection."
3.	Keratitis 10/01/1991 - "A multicenter, prospective clinical study of 148 culture-proven cases of bacterial keratitis, treated with ciprofloxacin 0.3% ophthalmic solution, compared its clinical and antibacterial efficacy with the standard therapy regimen of each investigator. " 04/01/2009 - "In this study, except for the Streptococcus species, ciprofloxacin was effective against the species responsible for severe bacterial keratitis." 01/01/2015 - "Ciprofloxacin (CIP) was effective in treating bacterial keratitis. " 02/01/2003 - "Ciprofloxacin therapy can be effective in the treatment of pneumococcal keratitis." 09/15/1992 - "Ciprofloxacin, a new broad-spectrum antibiotic effective against a variety of gram-positive and gram-negative bacteria, has recently become available in topical ophthalmic solution (3 mg/ml) for the treatment of bacterial keratitis. "
4.	Pneumonia (Pneumonitis) 03/01/2003 - "We report here two cases of Legionella pneumophila pneumonia that were markedly improved by parenteral ciprofloxacin administration. " 10/01/2002 - "Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia. " 08/01/2002 - "In the present study the therapeutic efficacy of pegylated liposomal ciprofloxacin was investigated in two rat models of Pseudomonas aeruginosa pneumonia. " 01/01/1991 - "Ciprofloxacin is effective in pneumonia but should be used only in cases where Streptococcus pneumoniae can be excluded as the causative agent." 08/01/1986 - "The therapeutic efficacy of ciprofloxacin in experimental guinea pig pneumonia due to L. "
5.	Endocarditis 06/01/1994 - "Antibacterial efficacy of ciprofloxacin in a case of endocarditis due to Cardiobacterium hominis." 03/01/1987 - "Using two strains of enterococci, we studied the efficacy of ciprofloxacin in the treatment of enterococcal experimental endocarditis in rabbits. " 11/01/2014 - "To report successful oral ciprofloxacin therapy for Neisseria elongata endocarditis. " 11/01/2014 - "Successful oral ciprofloxacin therapy of Neisseria elongata endocarditis." 07/01/2004 - "More cases of gonococcal endocarditis (a rare complication of gonorrhoea) may occur with the increase in the incidence of gonorrhoea and the increase in resistance to ciprofloxacin, which is currently used as the first line agent for the treatment of gonorrhoea in 75% of genitourinary medicine clinics."

Related Drugs and Biologics

1.	Ofloxacin (Levofloxacin)
2.	Metronidazole (Metric)
3.	Doxycycline (Vibramycin)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Tobramycin (Nebcin)
6.	Rifampin (Rifampicin)
7.	Ceftazidime (Fortum)
8.	Gentamicins (Gentamicin)
9.	Norfloxacin
10.	Clarithromycin (Biaxin)

Related Therapies and Procedures

1.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)
4.	Catheters
5.	Aftercare (After-Treatment)